Answers are grounded in this paper and cite their sources.
Tinospora cordifolia is a recognized medicinal plant recognized for its substantial immunomodulatory capabilities, which are ascribed to bioactive compounds like cordifoliside A and syringin. This study sought to formulate and assess a patient-friendly nutraceutical jelly using Tinospora cordifolia extract through a 3² factorial design. The optimized formulation (F6) had favourable physicochemical characteristics, with a viscosity of 3859–3862 cP, a pH of 6.8, and an extract content of 97.12%. In vitro dissolution experiments revealed a maximum cumulative extract release of 96.94% within 60 min, signifying effective drug release. Phytochemical and FTIR analyses validated the existence of essential functional groups and the compatibility between the extract and excipients. Stability studies performed under accelerated settings (40°C ± 2°C / 75% RH) shown no major alterations over a period of 90 days. The in-vivo immunomodulatory assessment utilizing a cyclophosphamide-induced myelosuppression model demonstrated a notable enhancement in hematological parameters. The formulation elevated hemoglobin levels to 15.35 ± 0.26 g/dL, RBC count to 8.85 ± 0.16 million cells/cmm, WBC count to 9979 ± 64.32 cells/cmm, and platelet count to 10.97 ± 0.46 lac/cmm in comparison to the immunosuppressed group. The results indicate that the formulated Tinospora cordifolia jelly exhibits substantial immunomodulatory effects, excellent stability, and high patient acceptability, rendering it a suitable nutraceutical delivery system for immunological enhancement.
No takes yet. Share an insight, caveat, or question.
Thombre et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: